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Abstract: PURPOSE To analyze and correlate preinterventional magnetic resonance (MR) imaging find-
ings with clinical symptoms after percutaneous sclerotherapy of venous malformations (VMs) adjacent
to the knee. MATERIALS AND METHODS Twenty-five patients (mean age, 24 y; range, 7-55 y; 11
female) with 26 VMs adjacent to the knee undergoing sclerotherapy (direct puncture, diagnostic angiog-
raphy, sclerosant injection) were identified, and MR imaging findings were analyzed. The VM involved
the synovium of the knee joint in 19 of 26 cases (76%). These lesions were associated with joint effusion
(3 of 19; 16%), hemarthrosis (4 of 19; 21%), or synovial thickening (16 of 19; 84%). Follow-up ended
6-8 weeks after the first or second sclerotherapy session if complete pain relief was achieved or 3 months
after the third sclerotherapy session. Treatment outcomes were categorized as symptom improvement
(complete or partial pain relief) or poor response (unchanged or increased pain). RESULTS Forty-nine
percutaneous sclerotherapy sessions were performed. Despite the absence of signs of knee osteoarthritis,
patients with a VM involving the synovium (8 of 14; 57%) showed a poor response to sclerotherapy (1
of 8 [13%] pain-free after 1 sclerotherapy session). Among patients with VMs with no associated joint
alteration and no synovial involvement (6 of 14; 43%), 5 of 6 (83%) showed improvement of symptoms
after 1 sclerotherapy session (P < .05). CONCLUSIONS Juxta-articular VMs of the knee are frequently
associated with hemarthrosis and synovial thickening. Patients with signs of osteoarthritis and synovial
involvement of the VM on presclerotherapy MR imaging deserve special consideration, as these findings
predict worse clinical symptoms after sclerotherapy.
DOI: https://doi.org/10.1016/j.jvir.2019.11.014






The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives
4.0 International (CC BY-NC-ND 4.0) License.
Originally published at:
Gnannt, Ralph; Guggenberger, Roman; Mueller, Daniel A; Neuhaus, Kathrin; Aufdenblatten, Christoph;
Theiler, Martin; Kellenberger, Christian J; Pfammatter, Thomas (2020). MR Features of Juxta-Articular
Venous Malformations of the Knee to Predict the Clinical Outcome of Sclerotherapy. Journal of Vascular
and Interventional Radiology, 31(4):551-557.
DOI: https://doi.org/10.1016/j.jvir.2019.11.014
2

































































Magnetic Resonance Features of Juxta Articular Venous Malformations of 
the Knee to Predict the Clinical Outcome of Sclerotherapy 
R. Gnannt 1•2, R. Guggenberger 1, D. A. Müller3, K. Neuhaus\ Ch. Aufdenblatten5, 
M. Theiler6, C.J. Kellenberger2, T. Pfarnmatter1 
1 Department ofDiagnostic and lnterventional Radiology, University Hospital Zurich, Zurich, Switzerland 
2 Diagnostic Imaging, University Children ' s Hospital Zurich, Zurich, Switzerland 
3 Orthopaedics, Der Balgrist - Universitätsklinik, Zurich, Switzerland 
4 Division ofPlastic and Reconstructive Surgery, Department ofSurgery, University Children's Hospital Zurich, 
Zurich, Switzerland 
5 Orthopaedics, Department ofSurgery, University Children' s Hospital Zurich, Zurich, Switzerland 
6 Division of Pediatric Dermatology, University Children ' s Hospital Zurich, Zurich, Switzerland 
Type of Manuscript: Original research 
Journal: Journal ofVascular and Interventional Radiology 
KeyWords: knee, venous, malformation, sclerotherapy, arthroscopy 
Conflict of Interest: The authors declare that they have no conflict of interest. 
Corresponding Author: Ralph Gnannt, MD 
E-mail: ralph.gnannt@usz.ch 











































To analyze and correlate pre-interventional magnetic resonance imaging (MRI) findings 
with clinical symptoms after percutaneous sclerotherapy treatment of venous malformations 
(VM) adjacent to the knee. 
MATERIAL AND METHODS: 
25 patients (mean age 24yrs, range 7-55yrs; 11 females) with 26 VMs adjacent to the 
knee undergoing sclerotherapy (direct puncture, diagnostic angiography, sclerosant injection) 
were identified and MRI findings were analyzed. The VM involved the synovium of the knee 
joint in 19/26 (76%) of all patients. These lesions were associated withjoint effusion (3/19, 
16%), hemarthrosis (4/19, 21 %) or synovial thickening (16/19, 84%). Follow up period of each 
patient ended 6 to 8 weeks after the first or second sclerotherapy session if complete pain relief 
was achieved or 3 months after the third sclerotherapy session. Treatment outcome was 

























(unchanged or increased pain). 
RESULTS: 
49 percutaneous sclerotherapy sessions were performed. Despite absence of signs of knee 
osteoarthritis patients with a VM involving the synovium (8/14, 57%) responded poorly to 



































































with VMs with no associatedjoint alteration and no synovial involvement (6/14, 43%) showed 
improvement of symptoms after one single sclerotherapy session in 5/6 (83%) patients (p<0.05). 
CONCLUSION: 
Juxta-articular VMs of the knee are frequently associated with hemarthrosis and synovial 
thickening. Patients with signs of osteoarthritis and synovial involvement of the VM on pre-












































Venous malformations (VM) are congenital, benign vascular anomalies consisting of 
deformed venous channels [1]. Depending on the extension of the VM, subcutaneous tissue, 
muscles, tendons or even bone may be involved [2][3]. If the VM is located adjacent to the knee 
joint early magnetic resonance imaging (MRI) is important to evaluate the exact juxta-articular 
extent ofthe lesion and its relation to differentjoint structures [4]. Additionally, MRI can be 
correlated with clinical symptoms and guide the interventional radiologist towards the optimal 
treatment location [5]. 
Indications for invasive treatment of a VM is persistent pain and impaired mobility, after 
conservative treatment has failed. The mainstay of invasive therapy of VMs nowadays is 
percutaneous sclerotherapy [6]. A wide variety of sclerosing agent with different mechanism of 
action on target tissue have been described in the literature [7]. Sodium Tetradecyl Sulfate (STS), 
ethanol, polidocanol, and bleomycin are the ones most commonly used [8][9][10]. However, the 

























size, extent ofthe VM and number of treatment sessions [11][12]. 
The aim of the study was to analyze pre-interventional magnetic resonance imaging and 
correlate the findings with the clinical symptoms of percutaneous sclerotherapy treatment of 
VM's adjacent to the knee joint in order to identify predictors for a favourable outcome of 



































































MATERIAL & METHODS 
Study Design: 
This retrospective cohort study was conducted in a tertiary referral teaching 
hospital. Institutional Research Ethics Board approval was obtained. The study cohort was 
identified from radiology reports on consecutive patients who had a VM adjacent to the knee 
joint identified on MRI and at least one session of percutaneous sclerotherapy with a 
percutaneous angiography performed. The knee joint was defined to extend from the distal 
femoral physis to the proximal tibial physis. The search period started January 2008 to ensure a 
sufficient sample size until December 2017 to allow adequate follow-up of all patients. 
Combinations of the following search words were used: magnetic resonance imaging, knee, 
venous malformation, vascular malformation, joint, lesion. If a patient underwent more than one 
MR examination, only the one prior to the sclerotherapy was reviewed. Only patients without 
prior treatment (percutaneous sclerotherapy, surgery) were included in the study. One patient 
with a Klippel-Trenauney syndrome was excluded from the study. 
MR examination 
The standard knee protocol with contrast at our institution was performed on a 1.5-Tesla 
scanner (Skyra, Siemens Medical, Healthineers, Erlangen, Germany) with an eight-channel 
phased array coil. The sequences obtained during MRI were the following: coronal turbo-
inversion recovery magnitude (TIRM, TR/TE=7470ms/38ms), sagittal proton density weighted 
sequence with fat saturation (PDfs, TR/TE=6690ms/38ms), axial Tl weighted turbos spin echo 



































































sequence (TR/TE=615ms/l lms) at 3mm slice thickness and increment, respectively. Respective 
field of views were adjusted to patient anatomy and size. 
Image review 
First, the images were reviewed by a radiologist with 10 years of experience to 
ensure MR findings are compatible with the diagnosis ofVM. A VM was defined as a T2 
hyperintense and Tl hypointense lesion with mixed contrast uptake (due to slow flow 
characteristic, phleboliths and/or thrombosis) [13]. To determine the exact location of a VM, the 
knee joint was separated into three parts according to the study form Jans et al : the superior third 
extended from the femoral physis to the inferior aspect of the suprapatellar pouch (A), the 
inferior third from the inferior aspect of the synovium of the knee to the tibial physis (C) and the 
middle third between the superior and inferior third (B) [4]. The approximate VM volume was 
calculated by averaging the measurements of the three planes (ap, lat, cc) [14]. Then the VM and 
the adjacent knee joint was assessed more in detail separately by two radiologists who were 
blinded to the final outcome (9 and 13 years of experience): extent of VM, (separate from knee 
joint, reaching capsule or reaching synovium), presence of joint effusion, hemarthrosis, synovial 
thickening, and hone involvement. In case of disagreement a third reader (32 years of 
experience) was included and the imaging assessed in a consensus manner between the three 
readers. 
Intraprocedural Venography and Sclerotherapy 
Depending on the sclerosant utilized, the number of punctures planned and the age ofthe 















local anesthesia (n=5) or none of them (n=2). Sonographie guided direct puncture of the VM was 
initially performed. Depending on the extent of the lesion at least one needle was placed into the 
VM. To study the intralesional needle positioning, the extension, volume and venous outflow of 
a VM, all patients received a phlebography by injecting contrast agent through each needle (non-




















































Giles, UK). We perform this as a routine procedure before injecting sclerosans. As a sclerosing 
agent either Sodium Tetradecyl Sulfate (Fibro-Vein ®, STD Pharrnaceutical Products Ltd., 
Hereford, U.K., 3% mixed with room air 1:1 to create a foam), ethanol 96% or Aethoxysclerol 
3% ® (Lauromacrogol 400, Kreussler Pharrna, Wiesbaden, Germany) was injected at the 
discretion ofthe investigator. The volume injected depended on the estimated volume after 
phlebography and the outflow of the lesion. If there was no or only partial pain relief after the 
first sclerotherapy session, a second treatment 6 to 8 weeks after the first one was performed and, 
if necessary, a third session another 6 to 8 weeks later using the same routine protocol. 
Follow-up period 
The follow up period of each patient ended 6 to 8 weeks after the first or second 
sclerotherapy session if complete pain relief was achieved or 3 months after the third 
sclerotherapy session disregarding whether pain relief was achieved. Clinical symptoms after 
treatment was extracted from the physician' s note during the last follow up visit and categorized 
according to the subjective patient symptoms of pain into O=complete pain relief, 1 =partial pain 




































































For statistical analysis SPSS version 23.0 for Windows (SPSS Inc., Chicago, IL) was 
used. Frequency distributions and cross-tabulations of variables of interest were obtained. The 
Shapiro-Wilk test was used to assess normal distribution. Results were expressed as mean ± SD 
or median where appropriate. Student's t-test or Mann-Whitney U test was used for group 
comparisons for continuous variables. Chi-square or Fisher exact test was used to compare 
categorical variables. Differences were considered significant at p<0.05 (two-tailed). The inter-
reader agreement was calculated using Cohen's kappa statistics. The inter-reader agreement was 





































































Between January 2008 and December 2017, 25 patients (14 males, 11 females, mean age 
of patients 24yrs, range 7-55yrs) with 26 VMs adjacent to knee joint with an MRI prior to any 
invasive treatment were identified and included in the study. One patient had bilateral knee VM. 
One patient had only an ultrasound of a small VM adjacent to knee joint and no MRI prior to 
percutaneous sclerotherapy and was not included in the study cohort of a total of 25 patients. 
The mean diameter of all VMs was 5.0cm (SD +/- 0.75cm, range 3.0cm -7.4cm). 3 
lesions were located in the upper third, 14 the middle third, and 9 in the lower third of the knee 
joint. 49 percutaneous sclerotherapy sessions were performed in 26 joints (mean sclerotherapy 
session per patient 1.9, range 1-3). On average 2.4 needles (range 1-5) were placed into the 
lesion per session and used for sclerotherapy agent injection. Out of all 49 sclerotherapy 
sessions, Ethanol 96% was used in 51% (25/49), Aethoxysclerol 3% in 14% (7/49) and STS 3% 
in 35% (17/49) as a sclerosing agent. Mean follow-up time was 351 days (range 43-1268 days). 
The VM involved the synovium ofthe kneejoint in 19/26 (73%) of all patients (K=0.71 ). 
In 5/26 (19%) the lesion was completely separate from the knee joint andin only 2/26 (8%) the 
VM involved the knee capsule. In those patients where the VM involved the synovium, joint 
effusion was seen in 16% (3/19), hemarthros in 21% (4/19), and synovial thickening in 84% 
(16/19). The pre-sclerotherapy MRI showed signs of joint degeneration in 11 out of 26 cases 
(42%) as defined as chondral lesions in 38% (10/26), subchondral sclerosis in 23% (6/26), and 















































Regarding clinical symptoms after sclerotherapy, out of the 26 knee VM 69% (18/26) 
were pain free (54%, 14/26) or had less pain (15%, 4/26) after the final clinical assessment after 
a mean of 1.6 (range 1-3) sclerotherapy sessions. 27% (7 /26) patients reported pain remained 
unchanged and one patient (4%, 1/26) experienced worsening pain after the final assessment. 
Therefore, in total 8 patients (31 %, 8/26) showed no positive response after a mean of 2.6 (range 
2-3) sclerotherapy treatments of their VM (Figure 1). 
Treatment response was then correlated with pre-interventional MRI findings. In those 8 
patients who responded poorly to sclerotherapy, synovial involvement was shown in 88% (7/8), 
chondral lesions in 75% (6/8), osteophytes in 38% (3/8) and subchondral sclerosis in 40% (4/8). 
Within the group of 18 patients with good treatment response VMs synovial involvement was 
seen in 67% (12/18), chondral lesions in 22% (4/18), osteophytes in 6% (1/18), and subchondral 
sclerosis in 11 % (2/18). In the group with good treatment response only 4/18 (22%) had signs of 
osteoarthritis compared to 7/8 (88%) in the group with poor response (p<0.01) . None of the 
patients showed hemarthrosis after sclerotherapy treatment during the follow up time (Table 1). 
Additionally, there was no significant difference in treatment outcome comparing sclerosing 
agents used for sclerotherapy treatment. Treatment outcome in correlation with the anatomical 




















However, patients without any signs of knee osteoarthritis on MR (regardless extent of 
the lesion; 15/26, 57%), 6 out of 15 patients ( 40%) showed improvement of symptoms after one 
single sclerotherapy session. In 8 ofthese 15 patients the VM involved the synovium and only 



































































sclerotherapy session (Figure 2). Compared to the patients where the VM showed no 
involvement of the synovium (and no signs of osteoarthritis, 7/15), 6 out of 7 (86%) reported 
complete or partial pain relief after one single sclerotherapy session (p<0.05) (Figure 3). 
However, there was no significant difference in overall treatrnent outcome regardless if the 












































VMs ofthe extremities may be asymptomatic and present as an incidental finding or may 
cause significant pain and potentially limb-threatening complications. One of the most disabling 
complications of VMs in the juxta articular knee area is recurrent hemarthrosis in the knee joint 
with consecutive cartilage destruction and long-term knee joint degenerative changes [15]. 
lntermittent bleeding into the joint space usually starts early in childhood and can be frequently 
observed in extensive VMs ofthe lower limb [16]. In our cohort, hemarthrosis was seen in 15% 
of all patients on MR imaging although number ofpatients with intermittent bleeding into the 
knee joint might be higher. 
Exposure of human cartilage tissue to blood leads to progressive damage of the joint 
surface and the underlying bone with consequently bad prognosis withjoint degeneration similar 
to hemophilia. The intraarticular blood leads to iron deposition and to cartilage denudation, 
degenerative joint changes and finally signs of osteoarthritis [17). These features mimic those 
typically encountered in haemophilic arthropathy or other causes of joint degeneration, such as 
























management [18]. Thus, radiologists are playing an important rote in correctly classifying the 
extent of a VM and consequently guide the multidisciplinary team that takes care of a patient 
with respect to therapeutic options. 
This study aimed to correlate MRI findings with clinical symptoms after sclerotherapy 
treatment for VMs of the knee area. Of this patient cohort of 26 juxta articular VM, 19 (73%) 















osteoarthritis of the knee has a high prevalence (9% at 20 years of age, 17% at 34 years of age ), 
our patient cohort of VMs adjacent to the knee joint showed a higher prevalence of knee 
osteoarthritis (mean age 24 years) [19][20]. 8 out ofthe 26 (31%) VMs showed hone 
involvement. Although Nakamura et al stated that absent of bone involvement in VM of the 



























patient with an unfavourable outcome showed boney involvement on pre-sclerotherapy MRI 
[21]. These results support the importance ofMRI in the evaluation of VMs and assessment of 
possible induced structural changes of the knee joint. 
In general, first line treatrnent after failed conservative management of a symptomatic 
VM is radiology guided percutaneous sclerotherapy with symptom relief in up to 95% [22]. 
Compared to the literature our patient cohort withjuxta articular VM ofthe knee showed an 
inferior response rate to sclerotherapy treatrnent (69% of patients reported complete or partial 
pain relief after a mean of 1.6 sclerotherapy sessions). One of the reasons might be the proximity 
of the VM close to a very mobile joint in an exposed location in the human body and therefore 





osteoarthritis and those patients responded poorly to sclerotherapy (7/8, 88%) compared to the 




















obvious that pain is at least partially induced by the degenerative changes of the knee joint itself 
and not only by the juxta articular knee VM. 
Even in patients without any signs of osteoarthritis (58% of the cohort) there was a 










































with or without synovial involvement. Only 13% ofthe patients with a VM involving the 
synovia of the knee joint reported partial or complete pain relief after one single sclerotherapy 
session (despite the absence of signs of osteoarthritis on pre-sclerotherapy MRI). However, 86% 
(6/7) of patients with no signs of osteoarthritis and no synovial involvement ofthe VM 
experienced partial or complete pain relief after one single sclerotherapy treatment (p<0.05). 
After treatment completion (up to three sclerotherapy sessions) there was no significant 
difference in treatment outcome regardless synovial involvement by malformed veins 
(p=0.3748). 
As previously shown surgical arthroscopy and wide synovectomy should be considered 
in all knee VMs involving the synovia. Dalmonte et al surgically resected 14 knee VM and all 
patients (mean age 5 years) were symptom free after a follow-up of 6 month [23] . He concluded, 
surgical excision is always indicated and should be performed as early as possible. Pireau et al 
highlighted the importance of early surgery in patients with intra-articular VM, even if 
asymptomatic to avoid hemarthrosis to protect the cartilage from further erosion [24]. In this 

























malformation adjacent to the knee joint. All of these patients were suffering from knee pain and 
hemarthrosis and in 5 patients, chondropathy was already present. After a mean follow-up of 
5.lyears only one patient suffered from reoccurrence ofhemarthrosis and none ofthe children 
had a substantial loss of function over time. 
The data in this study suggests, that VMs adjacent to the knee joint are difficult to 















special considerations and this data at least question sclerotherapy as a first line treatment. 
Another therapeutic approach is to embolize the VM adjacent to the knee joint with N-butyl-2-
cyanoacrylate to control bleeding and to facilitate surgical resection [25] . Uller et al embolized 
with this technique seven intra-articular VMs of the knee prior to resection with a follow-up time 



























from hemarthrosis and consecutive osteoarthropathy in the long term. Further investigation is 
needed, if a combined therapeutic approach is better to help those patients in the long term: early 
synovectomy and percutaneous sclerotherapy of the residual VM. 
This study has limitations. First, the sample size is small. Second, there was a variety of 
sclerotherapeutic agent used in this patient cohort, the agent was chosen by the interventional 
radiologist. The cohort showed no significant difference regarding sclerotherapeutic agent used 
and the clinical symptoms after sclerotherapy. Additionally, there is no prospective study which 
compares different sclerosing agent. Reoccurrence of pain after sclerotherapy of VMs is a very 
well known problem. During our relatively short follow-up time, there was no relapse reported in 





correlate those with the clinical symptoms after sclerotherapy treatment. Third, we did not 




















treatment. Caty et al found a tendency of higher contrast uptake at 10 minutes post contrast in 
patients who responded to percutaneous sclerotherapy treatment. However, other studies 
demonstrated, that clinical outcome after sclerotherapy treatment of VMs do not necessarily 



































































In conclusion, symptomatic juxta articular VM of the knee joint are frequently associated 
with hemarthrosis and synovial thickening. Patients with signs of osteoarthritis and synovial 
involvement ofthe VM on pre-sclerotherapy MR deserve special consideration as these findings 
hamper the clinical symptoms after sclerotherapy. An additional assessment of the affected knee 
joint by an orthopaedist who is familiar with vascular anomalies before the first sclerotherapy 
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Flow Chart ofthe clinical outcome ofthe patient cohort. Patients had less or were free of pain 
after a mean of 1.6 (range 1-3) sclerotherapy sessions. The poor responders had a mean of 2.6 
(range 2-3) sclerotherapy sessions. 
Table 1: 
Clinical symptoms in correlation with age, VM diameter & anatomical location, MR features , 
hemarthrosis, and sclerotherapeutic agent used. * range in brackets. 
Anatomical location of the VM: superior third extended from the femoral physis to the inferior 
aspect of the suprapatellar pouch (A), middle third between the superior and inferior third (B) 
inferior third from the inferior aspect of the synovium of the knee to the tibial physis (C) 
FIGURES 
Figure 1: 
Flow Chart of the clinical outcome of the patient cohort. Patients had less or were free of pain 
after a mean of 1.6 (range 1-3) sclerotherapy sessions. The poor responders had a mean of 2.6 
(range 2-3) sclerotherapy sessions. 
Figure 2: 
(a) Sagittal T2 weighted fat saturated image of the knee of a 33 years old male patient. Patient 
had an extensive VM ofthe knee with synovial involvement (arrows). (b) & (c) Despite there 
were no signs of osteoarthritis on pre-treatment MR patient was still symptomatic after three 
sclerotherapy sessions. 
Figure 3: 
(a) & (b) Sagittal and coronal T2 weighted, fat saturated images ofthe knee of a 12 year old male 
with a venous malformation without involvement ofthe synovia and no signs of osteoarthritis. 
(c) & (d) Afterultrasound guided needle placement angiography was perfomed which shows the 
extent ofthe VM. Patient was pain free after one sclerotherapy session with STS. 
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